Inflammatory Breast Cancer Clinical Trials
The Morgan Welch Inflammatory Breast Cancer Research Program is committed to finding what causes inflammatory breast cancer and identifying new treatment options. We are conducting a number of treatment-based studies and a wide variety of lab-based studies to understand this disease better. The list below highlights the ongoing trials being run by the IBC research program and clinic. Additional IBC clinical trials can be found at ClinicalTrials.gov.
If you would like more information about becoming involved with our clinical trials in general, you may email our program at ibcp@mdanderson.org.
IBC Registry
Protocol 2006-1072: Inflammatory breast cancer registry
Contact Info:
Study Manager: Angela Alexander Ph.D., Tel: 713-792-9137, Email: aalexand@mdanderson.org
Principal Investigator: Naoto Ueno, M.D., Tel: 713-792-8754, Email: nueno@mdanderson.org
Currently Open Trials for Newly Diagnosed IBC
Protocol 2020-0715: Enhancing Immunotherapy by targeting the EGFR pathway in Inflammatory Breast Cancer: A phase II study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in combination with neoadjuvant chemotherapy (NAC) in patients with newly diagnosed triple negative inflammatory breast cancer (TN-IBC)
Contact Info:
Study Manager: Angela Marx R.N., Tel: 713-792-5355, Email: anmarx@mdanderson.org
Principal Investigator: Naoto Ueno M.D. Ph.D., Tel: 713-792-8754, Email: nueno@mdanderson.org
Currently Open Trials for Adjuvant Treatment
Protocol 2016-0096: A phase II study of anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy.
Study Manager: Angela Alexander Ph.D., Tel: 713-792-9137, Email: aalexand@mdanderson.org
Principal Investigator: Clinton Yam M.D., Tel: 832-589-8343, Email: cyam@mdanderson.org
Protocol 2018-0550: Atorvastatin in triple-negative breast cancer (TNBC) patients who did not achieve a pathologic complete response (pCR) after receiving neoadjuvant chemotherapy
Study Manager: Angela Alexander Ph.D., Tel: 713-792-9137, Email: aalexand@mdanderson.org
Principal Investigator: Carlos Barcenas M.D., Tel: 713-794-5098, Email: chbarcenas@mdanderson.org
Currently Open Trials for Metastatic/Recurrent IBC
Protocol 2014-0533: A phase II study of anti-PD1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (IBC) or nonIBC triple negative breast cancer (TNBC) who have achieved clinical response or stable disease to prior chemotherapy
Contact Info:
Study Manager: Vivian Chiv, R.N. MSN, Tel: 713-792-4157, Email: vychiv@mdanderson.org
Principal Investigator: Naoto Ueno, M.D. PhD., Tel: 713-792-8754, Email: nueno@mdanderson.org
Protocol 2016-0890: A phase II study of triple combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab + Eribulin (AE) in patietns with recurrent/metastatic inflammatory breast cancer.
Contact Info:
Study Manager: Angela Alexander Ph.D., Tel: 713-792-9137, Email: aalexand@mdanderson.org
Principal Investigator: Vicente Valero, M.D., Tel: 713-563-0751, Email: vvalero@mdanderson.org
Protocol 2016-1096: A phase I study of OTS167 PO, a MELK inhibitor, to evaluate safety, tolerability and pharmacokinetics in patients with advanced breast cancer and dose-expansion study in patients with triple negative breast cancer
Contact Info:
Study Manager: Vivian Chiv, RN, MSN, Tel: 713-792-4157, Email: vychiv@mdanderson.org
Principal Investigator: Naoto Ueno, M.D. Ph.D., Tel: 713-792-8754, Email: nueno@mdanderson.org
Protocol 2021-0077: A phase Ib/II study of grapiprant (IK-007) and eribulin combination treatment for metastatic inflammatory breast cancer (mIBC)
Contact Info:
Study Manager: Angela Marx, R.N., Tel: 713-792-5355, Email: anmarx@mdanderson.org
Principal Investigator: Naoto Ueno, M.D. Ph.D., Tel: 713-792-8754, Email: nueno@mdanderson.org
Protocol 2021-0327: A phase 1, first-in-human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors (Only enrolling breast cancer patients at MD Anderson)
Contact Info:
Study Manager: Angela Alexander, Ph.D., Tel: 713-792-9137, Email: aalexand@mdanderson.org
Principal Investigator: Naoto Ueno, M.D. Ph.D., Tel: 713-792-8754. Email: nueno@mdanderson.org